Protalix BioTherapeutics (PLX) Change in Cash (2010 - 2026)

Protalix BioTherapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at $26.3 million for Q1 2026.

• In Q1 2026, Change in Cash rose 8815.56% year-over-year to $26.3 million; the TTM figure through Mar 2026 stood at $21.5 million (up 377.94% YoY), while the FY2025 annual figure was -$5.1 million, down 31.13% from the prior year.
• Change in Cash was $26.3 million for Q1 2026 at Protalix BioTherapeutics, up from $1.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $26.3 million in Q1 2026 to a low of -$27.8 million in Q3 2023.
• Historically, Change in Cash has averaged $118588.2 across 5 years, with a median of -$302000.0 in 2025.
• The sharpest annual moves came in 2022 and 2026: Change in Cash tumbled 1511.95% in 2022, then soared 8815.56% in 2026.
• A 5-year view of Change in Cash shows it stood at $6.4 million in 2022, then sank by 49.52% to $3.2 million in 2023, then tumbled by 337.1% to -$7.6 million in 2024, then surged by 113.51% to $1.0 million in 2025, then surged by 2448.02% to $26.3 million in 2026.
• The last three Change in Cash figures came in at $26.3 million (Q1 2026), $1.0 million (Q4 2025), and -$4.2 million (Q3 2025), per Business Quant data.